Rhythm Pharmaceuticals sees FY25 non-GAAP operating expense $285M-$315M

For the year ending December 31, 2025, Rhythm anticipates approximately $285 million to $315 million in Non-GAAP Operating Expenses. Non-GAAP Operating Expenses are derived from: GAAP total operating expenses, inclusive of: SG&A expenses of approximately $135 million to $145 million; R&D expenses of approximately $150 million to $170 million; and Excluding stock-based compensation.